Form 4 for ZVRA ZEVRA THERAPEUTICS, INC.
Accepted 2026-02-02 00:00:00 ET · period of report 2026-01-29 · accession 0001910132-26-000002 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-02 | 2026-01-30 | ZVRA | Quartel Adrian W | Chief Medical Off | S - Sale+OE | $8.83 | -4,533 | 9,723 | -32% | -$40.0K |
| D | 2026-02-02 | 2026-01-30 | ZVRA | Quartel Adrian W | Chief Medical Off | M - OptEx | — | +11.3K | 14.3K | +388% | — |
| DM | 2026-02-02 | 2026-01-29 | ZVRA | Quartel Adrian W | Chief Medical Off | A - Grant | $0.00 | +112.5K | 75.0K | New | $0 |
| D | 2026-02-02 | 2026-01-30 | ZVRA | Quartel Adrian W | Chief Medical Off | M - OptEx | $0.00 | -11.3K | 22.7K | -33% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-30 | S | D | 4,533 | $8.83 | 9,723 | D | — | — | (F3) This transaction was executed in multiple trades at prices ranging from $8.62 to $9.04. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2026-01-30 | M | A | 11,333 | — | 14,256 | D | — | — | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. |
| 3 | Derivative | Restricted Stock Unit | 2026-01-29 | A | A | 37,500 | $0.00 | 37,500 | D | — · — to — | 37,500 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F4) The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date. |
| 4 | Derivative | Stock Option (right to buy) | 2026-01-29 | A | A | 75,000 | $0.00 | 75,000 | D | $8.86 · — to 2036-01-28 | 75,000 Common Stock | (F5) Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. |
| 5 | Derivative | Restricted Stock Unit | 2026-01-30 | M | D | 11,333 | $0.00 | 22,667 | D | — · — to — | 11,333 Common Stock | (F1) Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. (F6) One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting Person's continued service through such vesting date. |